Geode Capital Management LLC raised its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,207 shares of the company's stock after purchasing an additional 458 shares during the quarter. Geode Capital Management LLC's holdings in argenx were worth $16,732,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Whipplewood Advisors LLC bought a new position in argenx in the 4th quarter valued at $37,000. Global Retirement Partners LLC increased its stake in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the period. Jones Financial Companies Lllp lifted its holdings in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after buying an additional 33 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after buying an additional 21 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.
argenx Price Performance
argenx stock traded up $8.06 during trading hours on Friday, hitting $608.57. 78,044 shares of the stock traded hands, compared to its average volume of 307,540. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21. The stock has a market capitalization of $37.16 billion, a price-to-earnings ratio of -691.51 and a beta of 0.60. The firm's 50 day moving average price is $598.76 and its 200-day moving average price is $607.23.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on ARGX shares. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Piper Sandler increased their price target on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. JMP Securities lifted their price objective on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and set a $720.00 target price on shares of argenx in a report on Tuesday, April 8th. Finally, Wedbush restated an "outperform" rating and issued a $715.00 price target on shares of argenx in a report on Friday, April 11th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $699.28.
Read Our Latest Analysis on argenx
argenx Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
